So far, the co-agonist drugs which have reached phase 2 trials have demonstrated an improved glycaemic profile with chronic administration
These side effects often result from increased cell growth, tissue expansion, and shifts in metabolic processes, which are more pronounced with higher doses or prolonged use
The PIONEER 3 study (Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial), consisting of 1864 subjects, tested the effectiveness of Rybelsus to Januvia (another DPP-4 inhibitor)
Fiber content which helps with digestion and managing weight loss drug or gain due to overeating, are known to reduce the risk of diabetes and heart disease
Other common renowned weight loss injectables include Mounjaro (Tirzepatide), Wegovy (Semaglutide), and Victoza (Liraglutide)
Both offer valuable avenues for scientific exploration in 2025